What is the role of papaverine injection for erectile dysfunction, what is the appropriate dose, and is it available in medical stores?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Papaverine for Erectile Dysfunction: Historical Role, Not Current Standard

Papaverine injection is NOT recommended as first-line therapy for erectile dysfunction and is explicitly contraindicated by the FDA for intracorporeal injection due to risk of persistent priapism. 1 While historically used in combination therapy, alprostadil (prostaglandin E1) remains the only FDA-approved intracavernosal injection medication. 2, 3

Historical Context and Current Status

Papaverine was introduced in the early 1980s as one of the first intracavernosal injection therapies for ED, typically combined with phentolamine to cause penile vasodilatation and smooth muscle relaxation. 2 However, the FDA explicitly states that papaverine hydrochloride is NOT indicated for treatment of impotence by intracorporeal injection and warns that such use has resulted in persistent priapism requiring medical and surgical intervention. 1

Why Alprostadil Replaced Papaverine

Alprostadil (PGE1) alone has FDA approval and remains the only officially approved drug for intracavernosal injection. 2, 3 The shift occurred because:

  • Alprostadil monotherapy provides adequate efficacy without requiring combination agents
  • Lower risk profile compared to papaverine-based regimens
  • Standardized dosing protocols (starting at 5 μg, titrated at 48-hour intervals) 2
  • Better safety profile, though penile pain occurs in 3-10% of patients 2

Dosing Information (Historical Reference Only)

When papaverine was used historically in combination therapy:

  • Papaverine + phentolamine: 30 mg/mL papaverine with 0.5-5 mg/mL phentolamine 4, 5
  • Triple therapy (trimix): 2.5 cc papaverine (30 mg/cc) + 0.5 cc phentolamine (5 mg/cc) + 0.05 cc PGE1 (500 μg/cc) 4
  • Typical doses ranged from 15-80 mg papaverine for self-injection 6
  • Doses above 80-100 mg increased risk of prolonged erections 7

Research showed that papaverine combinations with PGE1 produced longer-duration erections than papaverine-phentolamine alone, but adding phentolamine to papaverine-PGE1 provided no additional benefit. 5

Availability in Medical Stores

Papaverine is NOT available as an FDA-approved formulation for erectile dysfunction treatment. 1 The FDA-approved papaverine hydrochloride injection (30 mg/mL) is indicated only for intravenous or intramuscular use in vascular spasm conditions, not for intracavernosal injection. 1

Compounding pharmacies may prepare "bimix" (papaverine + phentolamine) or "trimix" (papaverine + phentolamine + alprostadil) formulations, but these are off-label uses. 3 Standard pharmacies typically stock only alprostadil for intracavernosal use. 3

Current Treatment Algorithm

For patients requiring intracavernosal injection therapy:

  1. First-line: Alprostadil monotherapy starting at 5 μg, titrated based on response 2
  2. Second-line: Combination therapy (bimix/trimix) from compounding pharmacies if monotherapy fails 3
  3. Never: Papaverine monotherapy due to FDA contraindication 1

Critical Safety Considerations

All intracavernosal injection therapy carries priapism risk (3-10% of patients). 2 Patients must:

  • Receive initial dose under physician supervision 3
  • Be counseled about prolonged erection management 3
  • Report erections lasting >4 hours immediately 2, 8
  • Have access to oral adrenergic agents (pseudoephedrine, ephedrine, terbutaline) for erections >1 hour 2
  • Seek emergency care if detumescence doesn't occur within 3 hours 2

Permanent corporal damage can occur if priapism goes untreated for >6 hours. 2

Modern Treatment Hierarchy

The current evidence-based approach prioritizes:

  1. Oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) as first-line 9, 8
  2. Intraurethral alprostadil for those preferring non-injection therapy 2, 3
  3. Intracavernosal alprostadil for PDE5i failures 3, 8
  4. Vacuum erection devices as non-pharmacologic option 2, 8
  5. Penile prosthesis for refractory cases 8

Bottom line: Papaverine should not be used as monotherapy for ED due to FDA contraindication and availability of safer, approved alternatives. If used at all, it should only be in physician-supervised combination therapy from compounding pharmacies, with alprostadil remaining the preferred intracavernosal agent. 2, 3, 1

References

2
Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

7
Research

[Induction of an erection using papaverine].

Urologiia i nefrologiia, 1989

8
Guideline

erectile dysfunction: aua guideline.

The Journal of urology, 2018

Related Questions

Is trimix (a mixture of papaverine, phentolamine, and alprostadil) safe in patients with a history of Myocardial Infarction (MI), stroke, and Cerebrovascular Accident (CVA)?
What is the appropriate dosing regimen, frequency, and safety precautions for using compounded injectable Trimix (alprostadil, papaverine, and phentolamine) to treat erectile dysfunction?
What is the proper use and dosage of Papaverine for medical treatment?
Is a papaverine 30mg and phentolamine 3mg combination safe for erectile dysfunction?
What is the appropriate starting dose for Trimix injections for erectile dysfunction?
What is the appropriate cetirizine (Zyrtec) dose for a child weighing 10 kilograms?
In a diabetic patient with autonomic and peripheral neuropathy and recent fatigue, can leg weakness indicate cardiovascular disease or myocardial infarction?
In an infant with suspected bacterial meningitis whose initial lumbar puncture was unsuccessful and who was started on vancomycin, ceftriaxone, and dexamethasone then switched to ampicillin and cefotaxime at meningitis doses, how many days of therapy should be given and what follow‑up is recommended?
In a patient with a central venous pressure of 6–7 cm H₂O, what is the appropriate fluid management?
What symptoms are associated with a serum sodium of 130 mEq/L (mild hyponatremia)?
What are the criteria for using the reduced dose of apixaban (Eliquis) in patients with atrial fibrillation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.